Benmoxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Benmoxin
Accession Number
DB09246
Type
Small Molecule
Groups
Withdrawn
Description

Benmoxin is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was synthesized in 1967 and was subsequently used as an antidepressant in Europe, but is now no longer marketed.

Structure
Thumb
Synonyms
  • Mebamoxine
International/Other Brands
Nerusil / Neuralex
Categories
UNII
XC9FY2SGBG
CAS number
7654-03-7
Weight
Average: 240.306
Monoisotopic: 240.126263143
Chemical Formula
C15H16N2O
InChI Key
BEWNZPMDJIGBED-UHFFFAOYSA-N
InChI
InChI=1S/C15H16N2O/c1-12(13-8-4-2-5-9-13)16-17-15(18)14-10-6-3-7-11-14/h2-12,16H,1H3,(H,17,18)
IUPAC Name
N'-(1-phenylethyl)benzohydrazide
SMILES
CC(NNC(=O)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Benmoxin.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Benmoxin.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Benmoxin.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Benmoxin.Experimental, Illicit
4-MethoxyamphetamineBenmoxin may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Benmoxin.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineBenmoxin may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Abediterol.Investigational
AcarboseBenmoxin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololBenmoxin may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Benmoxin.Experimental
AlbiglutideBenmoxin may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Benmoxin.Approved, Illicit
AliskirenBenmoxin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Benmoxin.Approved, Investigational
AlogliptinBenmoxin may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Benmoxin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Benmoxin.Illicit
AlprenololBenmoxin may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Benmoxin.Approved
AmbrisentanBenmoxin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineBenmoxin may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineBenmoxin may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideBenmoxin may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineBenmoxin may increase the hypotensive activities of Amlodipine.Approved
AmoxapineBenmoxin may increase the serotonergic activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Benmoxin.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Benmoxin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Arformoterol.Approved, Investigational
AtenololBenmoxin may increase the hypotensive activities of Atenolol.Approved
AtomoxetineBenmoxin may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineBenmoxin may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bambuterol.Approved, Investigational
BenazeprilBenmoxin may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBenmoxin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Benmoxin.Approved, Illicit
BepridilBenmoxin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Benmoxin.Approved, Investigational
BetaxololBenmoxin may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineBenmoxin may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bezafibrate.Approved, Investigational
BietaserpineBenmoxin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostBenmoxin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBenmoxin may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bitolterol.Withdrawn
BosentanBenmoxin may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Benmoxin may increase the hypotensive activities of BQ-123.Investigational
BretyliumBenmoxin may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Benmoxin.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Brimonidine.Approved
BrofaromineBenmoxin may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Benmoxin.Approved, Investigational
BupranololBenmoxin may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benmoxin.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Benmoxin is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benmoxin.Approved, Illicit, Vet Approved
ButriptylineBenmoxin may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Benmoxin.Approved
CadralazineBenmoxin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineBenmoxin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinBenmoxin may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanBenmoxin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilBenmoxin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilBenmoxin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilBenmoxin may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benmoxin.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Benmoxin.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Benmoxin.Approved, Investigational
CaroxazoneBenmoxin may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololBenmoxin may increase the hypotensive activities of Carteolol.Approved
CarvedilolBenmoxin may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololBenmoxin may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideBenmoxin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Benmoxin.Illicit, Withdrawn
ChlorpropamideBenmoxin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneBenmoxin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineBenmoxin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilBenmoxin may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Benmoxin.Approved, Investigational
CirazolineBenmoxin may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Benmoxin.Approved
ClemastineBenmoxin may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineBenmoxin may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineBenmoxin may increase the hypertensive activities of Clonidine.Approved
CloranololBenmoxin may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Benmoxin.Approved, Illicit
CryptenamineBenmoxin may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Benmoxin.Approved
CyclopenthiazideBenmoxin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideBenmoxin may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineBenmoxin may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinBenmoxin may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Benmoxin.Investigational
DebrisoquinBenmoxin may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilBenmoxin may increase the hypotensive activities of Delapril.Experimental
DeserpidineBenmoxin may increase the hypotensive activities of Deserpidine.Approved
DesipramineBenmoxin may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Benmoxin.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateBenmoxin may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Benmoxin.Approved, Illicit
DextromethorphanBenmoxin may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Benmoxin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benmoxin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Benmoxin.Approved, Investigational
DiazoxideBenmoxin may increase the hypotensive activities of Diazoxide.Approved
DibenzepinBenmoxin may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineBenmoxin may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionBenmoxin may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineBenmoxin may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benmoxin.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Benmoxin.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Benmoxin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benmoxin.Experimental, Illicit
DiltiazemBenmoxin may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineBenmoxin may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benmoxin.Approved, Illicit
DipivefrinBenmoxin may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideBenmoxin may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Benmoxin is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideBenmoxin may increase the hypotensive activities of Dorzolamide.Approved
DosulepinBenmoxin may increase the serotonergic activities of Dosulepin.Approved
DoxapramBenmoxin may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinBenmoxin may increase the hypotensive activities of Doxazosin.Approved
DoxepinBenmoxin may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Doxofylline.Approved, Investigational
DoxylamineBenmoxin may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Benmoxin.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Benmoxin.Experimental, Illicit
DroxidopaBenmoxin may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideBenmoxin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Benmoxin.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Benmoxin.Experimental, Illicit
EfonidipineBenmoxin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Benmoxin.Approved, Investigational
EmpagliflozinBenmoxin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilBenmoxin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBenmoxin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineBenmoxin may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Benmoxin.Approved, Investigational
EpanololBenmoxin may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Benmoxin is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineBenmoxin may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolBenmoxin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBenmoxin may increase the hypotensive activities of Eprosartan.Approved
ErgonovineBenmoxin may increase the hypertensive activities of Ergonovine.Approved
ErgotamineBenmoxin may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Benmoxin.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Benmoxin.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benmoxin.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Benmoxin.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Benmoxin.Illicit, Vet Approved
ExenatideBenmoxin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineBenmoxin may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineBenmoxin may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamBenmoxin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benmoxin.Approved, Illicit, Investigational, Vet Approved
Ferulic acidBenmoxin may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Benmoxin.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Benmoxin.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Benmoxin.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Formoterol.Approved, Investigational
FosinoprilBenmoxin may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Benmoxin.Approved, Investigational
FurazolidoneBenmoxin may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Benmoxin.Experimental
GliclazideBenmoxin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBenmoxin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBenmoxin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideBenmoxin may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzBenmoxin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelBenmoxin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineBenmoxin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineBenmoxin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineBenmoxin may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorBenmoxin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBenmoxin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBenmoxin may increase the hypotensive activities of Guanoxan.Experimental
HarmalineBenmoxin may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Benmoxin.Approved, Illicit, Investigational
HexamethoniumBenmoxin may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the hypertensive activities of Benmoxin.Experimental
HydralazineBenmoxin may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBenmoxin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Benmoxin.Approved, Illicit
HydroflumethiazideBenmoxin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benmoxin.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Benmoxin.Approved
ImidaprilBenmoxin may increase the hypotensive activities of Imidapril.Investigational
ImipramineBenmoxin may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Benmoxin.Investigational, Withdrawn
IndapamideBenmoxin may increase the hypotensive activities of Indapamide.Approved
IndenololBenmoxin may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminBenmoxin may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartBenmoxin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirBenmoxin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineBenmoxin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineBenmoxin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanBenmoxin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproBenmoxin may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Benmoxin.Approved
IprindoleBenmoxin may increase the serotonergic activities of Iprindole.Experimental
IproclozideBenmoxin may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Benmoxin.Withdrawn
IrbesartanBenmoxin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Benmoxin.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Isoprenaline.Approved, Investigational
IsradipineBenmoxin may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinBenmoxin may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Benmoxin.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Benmoxin.Approved, Nutraceutical, Withdrawn
LabetalolBenmoxin may increase the hypotensive activities of Labetalol.Approved
LacidipineBenmoxin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostBenmoxin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineBenmoxin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Benmoxin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benmoxin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Benmoxin.Approved, Investigational
LevonordefrinBenmoxin may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benmoxin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Benmoxin is combined with Linezolid.Approved, Investigational
LinsidomineBenmoxin may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideBenmoxin may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Benmoxin.Approved, Investigational
LisinoprilBenmoxin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Benmoxin.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Benmoxin is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Benmoxin.Illicit
LofepramineBenmoxin may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Benmoxin.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Benmoxin.Approved
LosartanBenmoxin may increase the hypotensive activities of Losartan.Approved
MacitentanBenmoxin may increase the hypotensive activities of Macitentan.Approved
ManidipineBenmoxin may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Maprotiline.Approved, Investigational
MebanazineBenmoxin may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineBenmoxin may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminBenmoxin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenBenmoxin may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Benmoxin.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Benmoxin.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Benmoxin.Experimental
MequitazineBenmoxin may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolBenmoxin may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminBenmoxin may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Benmoxin.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Benmoxin.Approved, Illicit
MethoserpidineBenmoxin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineBenmoxin may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Benmoxin.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Benmoxin is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Benmoxin.Experimental
Methylene blueBenmoxin may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateBenmoxin may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Benmoxin.Approved
MetipranololBenmoxin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneBenmoxin may increase the hypotensive activities of Metolazone.Approved
MetoprololBenmoxin may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineBenmoxin may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Mianserin.Approved, Investigational
MibefradilBenmoxin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineBenmoxin may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Benmoxin.Experimental, Illicit, Investigational
MifepristoneBenmoxin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolBenmoxin may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Benmoxin.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Benmoxin.Approved
MinoxidilBenmoxin may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Benmoxin.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Benmoxin is combined with Moclobemide.Approved, Investigational
MoexiprilBenmoxin may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Benmoxin.Approved, Investigational
MoxonidineBenmoxin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineBenmoxin may increase the hypotensive activities of Muzolimine.Experimental
NadololBenmoxin may increase the hypotensive activities of Nadolol.Approved
NaftopidilBenmoxin may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benmoxin.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Benmoxin.Investigational
NaphazolineBenmoxin may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Benmoxin.Approved, Investigational
NateglinideBenmoxin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololBenmoxin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Benmoxin.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Benmoxin.Withdrawn
NicardipineBenmoxin may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilBenmoxin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineBenmoxin may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBenmoxin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineBenmoxin may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineBenmoxin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineBenmoxin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideBenmoxin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineBenmoxin may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Benmoxin.Approved, Illicit
NortriptylineBenmoxin may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinBenmoxin may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineBenmoxin may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanBenmoxin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Olodaterol.Approved
OmapatrilatBenmoxin may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolBenmoxin may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Benmoxin.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Orciprenaline.Approved
OxprenololBenmoxin may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Benmoxin is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineBenmoxin may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benmoxin.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Benmoxin.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Benmoxin.Approved, Investigational
PenbutololBenmoxin may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineBenmoxin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benmoxin.Approved, Vet Approved
PentoliniumBenmoxin may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Benmoxin.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilBenmoxin may increase the hypotensive activities of Perindopril.Approved
PethidineBenmoxin may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Benmoxin is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Benmoxin.Experimental
PhendimetrazineBenmoxin may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Benmoxin.Approved
PheniprazineBenmoxin may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Benmoxin.Experimental
PhenoxybenzamineBenmoxin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineBenmoxin may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Benmoxin.Approved, Illicit
PhentolamineBenmoxin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineBenmoxin may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Benmoxin.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Benmoxin.Investigational
PinacidilBenmoxin may increase the hypotensive activities of Pinacidil.Approved
PindololBenmoxin may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneBenmoxin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Benmoxin.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Benmoxin.Approved
PivhydrazineBenmoxin may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenBenmoxin may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorBenmoxin may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideBenmoxin may increase the hypotensive activities of Polythiazide.Approved
PramlintideBenmoxin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinBenmoxin may increase the hypotensive activities of Prazosin.Approved
ProcaineBenmoxin may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineBenmoxin may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Procaterol.Approved, Investigational
PropranololBenmoxin may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Protokylol.Approved, Vet Approved
ProtriptylineBenmoxin may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Benmoxin.Approved
QuinaprilBenmoxin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineBenmoxin may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineBenmoxin may increase the hypertensive activities of Racepinephrine.Approved
RamiprilBenmoxin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Benmoxin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benmoxin.Approved
RemikirenBenmoxin may increase the hypotensive activities of Remikiren.Approved
RepaglinideBenmoxin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineBenmoxin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Reserpine.Approved, Investigational
RilmenidineBenmoxin may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatBenmoxin may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Benmoxin.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Benmoxin.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Benmoxin.Approved, Investigational
RosiglitazoneBenmoxin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Benmoxin.Approved
SafrazineBenmoxin may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salmeterol.Approved
SaprisartanBenmoxin may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinBenmoxin may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Benmoxin.Approved, Investigational, Vet Approved
SelexipagBenmoxin may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Benmoxin.Approved
SitagliptinBenmoxin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanBenmoxin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilBenmoxin may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benmoxin.Approved, Investigational
SulfadiazineBenmoxin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleBenmoxin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleBenmoxin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Benmoxin.Approved, Investigational
SunitinibBenmoxin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololBenmoxin may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Benmoxin.Approved
TelmisartanBenmoxin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilBenmoxin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Terbutaline.Approved
TerlipressinBenmoxin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Benmoxin is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Benmoxin.Investigational
TetrahydropalmatineBenmoxin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineBenmoxin may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineBenmoxin may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Benmoxin.Approved, Investigational
TiboloneBenmoxin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenBenmoxin may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Benmoxin.Experimental
TimololBenmoxin may increase the hypotensive activities of Timolol.Approved
TolazamideBenmoxin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineBenmoxin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBenmoxin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benmoxin.Approved, Withdrawn
TolonidineBenmoxin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Benmoxin.Approved
TorasemideBenmoxin may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Benmoxin.Approved, Investigational
TrandolaprilBenmoxin may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Benmoxin.Approved, Investigational
TravoprostBenmoxin may increase the hypotensive activities of Travoprost.Approved
TrazodoneBenmoxin may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilBenmoxin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideBenmoxin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBenmoxin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanBenmoxin may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineBenmoxin may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneBenmoxin may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilBenmoxin may increase the hypotensive activities of Urapidil.Investigational
ValsartanBenmoxin may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Benmoxin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Benmoxin is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Benmoxin.Approved
VincamineBenmoxin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBenmoxin may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Benmoxin.Approved, Investigational
XipamideBenmoxin may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBenmoxin may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Benmoxin.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Benmoxin.Approved
ZofenoprilBenmoxin may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Benmoxin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
71671
PubChem Substance
310265149
ChemSpider
64728
ChEBI
134978
ChEMBL
CHEMBL1877495
Wikipedia
Benmoxin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0289 mg/mLALOGPS
logP2.26ALOGPS
logP2.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)14.47ChemAxon
pKa (Strongest Basic)3.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity82.98 m3·mol-1ChemAxon
Polarizability26.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acids and derivatives. These are organic compounds containing a carboxylic acid substituent attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acids and derivatives
Alternative Parents
Benzoyl derivatives / Carboxylic acid hydrazides / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Benzoic acid or derivatives / Benzoyl / Carboxylic acid hydrazide / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 16:19 / Updated on June 02, 2018 08:18